RenovoRx reports Q3 EPS (8c), two estimates (8c)

Reports Q3 revenue $266K, consensus $304K. Cash and cash equivalents as of September 30, 2025 were $10M. The company states it believes this cash is sufficient to fund ongoing commercialization efforts and the completion of enrollment in its Phase III TIGeR-PaC clinical trial in early 2026. CEO Shaun Bagai said, “On the commercial side, we are encouraged by the continued RenovoCath clinical adoption we are seeing in the field. Year-to-date revenue, through the end of the third quarter, was approximately $900,000, reflecting the growing clinical need and market demand for targeted drug-delivery solutions. Since organically launching commercial sales less than a year ago, we have expanded from five centers at the start of 2025 to 14 leading cancer centers now approved to purchase RenovoCath, including several that have already made repeat orders.”